ArticleInvestigational new drugs2021

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.

Antoine Italiano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.